XBIO

Xenetic Biosciences Inc

1.99

Oct 16 • 3:56 PM ET -0.02 (-1.00%)

1.99

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Oct 15, 9:25 AMXenetic Biosciences doses first patient in systemic DNase plus CAR T study for large B-cell lymphoma

Peers: APRE GOVX KAPA KPRX LNAI BCDA BIVI CVM NEUP CALC

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	4.66M
Enterprise Value	-1.81M
Income	-2.48M
Sales	3.26M
Book/sh	2.59
Cash/sh	2.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2
IPO	Jun 19, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	1.43
P/B	0.77
P/C	0.72
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.56
Quick Ratio	7.43
Current Ratio	7.43
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.19
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	30.07% 37.89%
Sales past 3/5Y	20.36% 46.78%
EPS Y/Y TTM	40.59%
Sales Y/Y TTM	33.30%
EPS Q/Q	9.27%
Sales Q/Q	11.99%
Earnings	Aug 07 BMO
EPS/Sales Surpr.	- -

Insider Own	15.70%
Insider Trans	0.00%
Inst Own	6.49%
Inst Trans	-19.80%
ROA	-40.17%
ROE	-47.04%
ROIC	-40.76%
Gross Margin	-
Oper. Margin	-81.01%
Profit Margin	-75.91%
SMA20	-12.39%
SMA50	-36.02%
SMA200	-30.29%
Trades

Shs Outstand	2.34M
Shs Float	1.98M
Short Float	0.65%
Short Ratio	0.15
Short Interest	0.01M
52W High	4.94 -59.71%
52W Low	1.87 6.42%
Volatility	6.63% 8.77%
ATR (14)	0.23
RSI (14)	31.70
Beta	2.36
Rel Volume	0.20
Avg Volume	87.17K
Volume	17,529

Perf Week	-6.57%
Perf Month	-19.11%
Perf Quarter	-29.18%
Perf Half Y	-43.63%
Perf YTD	-8.29%
Perf Year	-54.67%
Perf 3Y	-50.37%
Perf 5Y	-88.94%
Perf 10Y	-99.64%
Recom	1.00
Target Price	2.50
Prev Close	2.01
Price	1.99
Change %	-1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-20	Initiated	Maxim Group	Buy	$2.50

Oct-15-26 08:46AM	Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma (ACCESSWIRE)
Sep-16-26 10:30AM	Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake (InvestorsHub) -48.71%
07:00AM	Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics (ACCESSWIRE)
Aug-07-26 08:35AM	Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform (ACCESSWIRE) +11.23%
03:32AM	Xenetic Biosciences: Q2 Earnings Snapshot (Associated Press)
08:40AM	Loading…
Jun-04-26 08:40AM	Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma (ACCESSWIRE)
Jun-01-26 09:02AM	Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival (ACCESSWIRE) +5.08%
May-13-26 08:05AM	Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform (ACCESSWIRE) +5.14%
May-12-26 04:58PM	Xenetic Biosciences: Q1 Earnings Snapshot (Associated Press)
Apr-22-26 09:00AM	Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting (ACCESSWIRE)
Mar-13-26 08:00AM	Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results (ACCESSWIRE) +9.46%
Mar-12-26 06:32PM	Xenetic Biosciences: Q4 Earnings Snapshot (Associated Press Finance)
Dec-11-25 05:00PM	Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting (ACCESSWIRE)
Nov-19-25 08:45AM	Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform (ACCESSWIRE)
Nov-13-25 08:45AM	Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results (ACCESSWIRE)
05:43PM	Loading…
Nov-12-25 05:43PM	Xenetic Biosciences: Q3 Earnings Snapshot (Associated Press Finance)
Oct-30-25 07:15AM	Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-10-25 09:30AM	Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock (ACCESSWIRE) -33.09%
Aug-13-25 08:00AM	Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results (ACCESSWIRE) +7.17%
Aug-12-25 06:25PM	Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:26PM	Xenetic Biosciences: Q2 Earnings Snapshot (Associated Press Finance)
Jul-30-25 09:00AM	Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma (ACCESSWIRE) -7.89%
Jul-23-25 08:30AM	Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform (ACCESSWIRE)
Jul-08-25 09:00AM	Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (ACCESSWIRE) +7.67%
May-14-25 08:05AM	Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (ACCESSWIRE)
Apr-22-25 05:15PM	USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates (Zacks) +5.37%
Apr-09-25 09:15AM	Xenetic Biosciences, Inc. Releases Virtual Investor 'What This Means' Segment (ACCESSWIRE) +5.03%
Mar-26-25 09:00AM	Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma (ACCESSWIRE)
Mar-19-25 08:05AM	Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results (ACCESSWIRE)
Mar-13-25 08:30AM	Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses (ACCESSWIRE) -5.57%
09:15AM	Loading…
Feb-27-25 09:15AM	Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting (ACCESSWIRE)
Dec-17-24 09:15AM	Xenetic Biosciences, Inc. Releases Virtual Investor 'What This Means' Segment (ACCESSWIRE)
Dec-16-24 09:00AM	Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform (ACCESSWIRE)
Dec-05-24 08:45AM	Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program (ACCESSWIRE)
Nov-22-24 09:15AM	Xenetic Biosciences, Inc. Releases Virtual Investor 'What This Means' Segment (ACCESSWIRE)
Nov-21-24 08:30AM	Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis (ACCESSWIRE)
Nov-13-24 08:30AM	Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results (ACCESSWIRE) -11.62%
Nov-12-24 09:00AM	Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models (ACCESSWIRE)
Nov-07-24 09:00AM	Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform (ACCESSWIRE) +7.65%
Oct-22-24 08:45AM	Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 (ACCESSWIRE)
Oct-17-24 08:45AM	Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform (ACCESSWIRE)
Sep-11-24 09:00AM	Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Aug-14-24 08:00AM	Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (ACCESSWIRE) -6.00%
Aug-13-24 10:54PM	XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024 (InvestorPlace) +7.03%
May-22-24 05:00PM	Xenetic Biosciences, Inc. Announces Executive Leadership Transition (ACCESSWIRE) +6.45%
May-10-24 08:30AM	Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update (ACCESSWIRE)
May-09-24 11:55PM	XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00PM	Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Mar-22-24 08:00AM	Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results (ACCESSWIRE)
07:53AM	XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Jan-17-24 09:00AM	Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform (ACCESSWIRE)
Nov-10-23 08:43AM	Xenetic Biosciences: Q3 Earnings Snapshot (Associated Press Finance)
08:35AM	Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results (ACCESSWIRE)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) -6.25%
Oct-11-23 09:05AM	Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference (ACCESSWIRE) +9.75%
Sep-05-23 08:05AM	Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-11-23 09:25AM	Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:24AM	Xenetic Biosciences: Q2 Earnings Snapshot (Associated Press Finance)
08:05AM	Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-10-23 05:30PM	Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-13-23 12:00PM	Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jul-05-23 08:45AM	Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series (ACCESSWIRE)
May-15-23 08:08AM	Xenetic Biosciences (NASDAQ:XBIO) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-12-23 12:30PM	Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock (ACCESSWIRE) -17.50%
May-11-23 04:42PM	Xenetic Biosciences: Q1 Earnings Snapshot (AP Finance)
04:30PM	Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (ACCESSWIRE)
May-04-23 08:35AM	Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development (ACCESSWIRE) +6.57%
May-03-23 08:35AM	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison (ACCESSWIRE)
Apr-11-23 08:30AM	Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform (ACCESSWIRE)
Mar-23-23 07:35AM	Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update (ACCESSWIRE)
Mar-16-23 08:05AM	Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event (ACCESSWIRE) +8.85%
Jan-17-23 08:05AM	Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy (ACCESSWIRE) +12.89%
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-05-23 08:05AM	Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event (ACCESSWIRE) +12.12%
Dec-15-22 06:05AM	Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All (Simply Wall St.)
Dec-01-22 05:47AM	This Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks Appropriate (Simply Wall St.)
Nov-16-22 08:35AM	Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform (ACCESSWIRE)
Nov-12-22 08:04AM	Xenetic Biosciences Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 07:05AM	Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update (ACCESSWIRE)
Oct-11-22 08:05AM	Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics (ACCESSWIRE)
Oct-04-22 08:00AM	Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board (ACCESSWIRE) +5.44%
Sep-07-22 08:05AM	Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Aug-12-22 08:00AM	Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update (ACCESSWIRE)
Aug-02-22 08:05AM	Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer (ACCESSWIRE)
Jul-07-22 09:00AM	Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study (ACCESSWIRE) +6.61%
Jun-02-22 02:00PM	JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences (ACCESSWIRE)
08:35AM	Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event (ACCESSWIRE)
May-18-22 08:15AM	Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference (ACCESSWIRE)
May-12-22 04:05PM	Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update (ACCESSWIRE) +6.45%
Apr-27-22 06:30AM	Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities (ACCESSWIRE) -7.81%
Mar-23-22 08:30AM	Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update (ACCESSWIRE)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Nov-12-21 08:00AM	Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update (ACCESSWIRE)
Nov-04-21 03:01PM	Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Sep-09-21 08:05AM	Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent (ACCESSWIRE)
Sep-08-21 08:00AM	Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (ACCESSWIRE)
Aug-13-21 08:05AM	Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update (ACCESSWIRE) -5.48%
Jul-30-21 11:30AM	15 Best High Volume Stocks to Buy Now (Insider Monkey) -23.21%
Jul-28-21 02:00PM	Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market (ACCESSWIRE)
Jul-27-21 08:27AM	Xenetic Biosciences (NASDAQ:XBIO) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

CFOMr. James F. Parslow

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XBIO

Xenetic Biosciences Inc

Upgrade your Finviz experience